ImmunityBio, Inc.: financial analysis
Ratios worked out from 10 fiscal years of ImmunityBio, Inc.'s statements, compared with 675 companies in Biotechnology.
ImmunityBio, Inc. scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in growth (2 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median50.9×Price to sales 50.9× against Biotechnology's median of 8.4×.
- ✗Free cash flow yield above 5%-3.3%Free cash flow is -3.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 4
- ✓Revenue grew in the newest year668.6%Revenue up 668.6% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.38 vs -0.62Diluted EPS -0.38 in fiscal 2025 against -0.62 the year before (report's currency).
- ✗Net income higher than five years earlier-$351 M-$351 M in fiscal 2025 against -$222 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$351 MNet income -$351 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-226.0%-226.0% against Biotechnology's median of -60.5% (246 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-226.0%-226.0% in fiscal 2025 against -146375.0% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities5.1×Current ratio 5.10 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-4.2×Operating income -4.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-5.68Z-score -5.68 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year31.3%Diluted shares up 31.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 3 years in a row.
Worth a look
- Net loss of $351 million, the 13th loss-making year in a row.
- Free cash flow was negative: -$309 million.
- The share count rose 31.3% in the year.
- Shareholders' equity is negative: -$500 million.
- Operating income covers the interest bill only -4.2 times.
- Receivables grew 1704% while revenue grew 669%: customers are paying later, or sales were booked ahead of cash.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseyes
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.50 | × 1.2 | 0.61 |
| Retained earnings to assets | -7.42 | × 1.4 | -10.40 |
| Operating income to assets | -0.51 | × 3.3 | -1.68 |
| Market value to liabilities | 9.28 | × 0.6 | 5.57 |
| Revenue to assets | 0.23 | × 1 | 0.23 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 99.3% | — | — | — | — | 74.8% | 98% | |
| Operating margin | -226.0% | — | — | — | — | -60.5% | 29% | |
| Net margin | -310.2% | — | — | — | — | -70.4% | 21% | |
| Return on equity | — | — | — | — | — | -61.5% | — | |
| Return on assets | -79.4% | -93.2% | -134.6% | -100.2% | -100.5% | -44.8% | 28% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 668.6% | — | — | — | — | 16.0% | 99% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | -4.20× | -3.00× | -2.81× | -5.53× | -22.24× | -22.46× | 81% | |
| Current ratio | 5.10× | 3.36× | 5.05× | 0.28× | 0.91× | 4.47× | 54% | |
| Equity share of assets | -99.7% | -127.7% | -116.4% | -123.5% | -51.7% | 64.2% | 8% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-309 M | $-398 M | $-397 M | $-416 M | $-308 M | $-40 M | 5% | |
| Free cash flow margin | -272.6% | — | — | — | — | -61.7% | 28% | |
| Capital spending share of revenue | 3.4% | 46.7% | — | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.26× | 0.03× | — | — | — | 0.26× | 49% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).